Clinical Trial Detail

NCT ID NCT02909972
Title Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Aileron Therapeutics
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

ALRN-6924 + Cytarabine

ALRN-6924

Age Groups: adult senior

No variant requirements are available.